Lv44
538 积分 2025-12-29 加入
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
17天前
已完结
Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia
1个月前
已完结
Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies
2个月前
已完结
皖公网安备34019202002308
